

**AMENDMENTS TO THE SPECIFICATION**

Please replace the paragraphs beginning on page 5, line 22, and ending on page 6, line 9, with the following:

-- The denatured collagen type-IV selective antagonists for use in the present invention have a core amino acid sequence L-K-Q-N-G-G-N-F-S-L [(SEQ ID NO: 1)].

A preferred denatured collagen type-IV selective antagonist for use in the present invention is a peptide having the amino acid sequence NH<sub>2</sub>-C-L-K-Q-N-G-G-N-F-S-L-G-COOH (CLK-peptide) [(SEQ ID NO: 2)].

Another preferred denatured collagen type-IV selective antagonist for use in the present invention is a peptide having the amino acid sequence NH<sub>2</sub>-S-L-K-Q-N-G-G-N-F-S-L-C-COOH (SLK peptide) [(SEQ ID NO: 3)].

Another preferred denatured collagen type-IV selective antagonist for use in the present invention is a peptide having the amino acid sequence NH<sub>2</sub>-K-G-G-C-L-K-Q-N-G-G-N-F-S-L-G-G-K-A-COOH (KGGCLK peptide) [(SEQ ID NO: 4)]. --

After page 37 and before the claims, please insert the paper copy of the Sequence Listing accompanying this Preliminary Amendment.